Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease

SÁNCHEZ NEGRETTE O; SÁNCHEZ VALDÉZ FJ; LACUNZA CD; GARCÍA BUSTOS MF; MORA MC; UNCOS AD; BASOMBRÍO MA

CLINICAL AND VACCINE IMMUNOLOGY

AMER SOC MICROBIOLOGY

Lugar: Washington, DC ; Año: 2008 vol. 15 p. 297 - 302

1556-6811

Serological tests are the main laboratory procedures used for diagnosis during the indeterminate and chronic stages of Chagas´ disease. A serological regression to negativity is the main criterion used to define parasitological cure in treated patients. The aim of this work was to monitor the individual specificities of antibody levels for 3 years posttreatment in 18 adult patients. Conventional serological techniques (hemagglutination assays and enzyme-linked immunosorbent assay [ELISA]) were modified by using recombinant antigens to detect early markers of treatment effectiveness. For this purpose, serum samples were taken before and during treatment and every 6 months after treatment for at least 3 years. When hemagglutination assays were used, a decrease in antibody levels was observed in only one patient. When ELISA with serum dilutions was used, antibody clearance became much more apparent: in 77.7% (14/18) of the patients, antibody titers became negative with time. This was observed at serum dilutions of 1/320 and occurred between the 6th and the 30th months posttreatment. The immune response and the interval for a serological regression to negativity were different for each patient. For some of the recombinant antigens, only 50% (9/18) of the patients reached the serological regression to negativity. Recombinant antigen 13 might be a good marker of treatment effectiveness, since 66.6% (six of nine) of the patients presented with an early regression to negativity for specific antibodies to this antigen (P = 0.002).